With the CHS-114 data set to debut at SITC 2025, spotlighting its cytolytic anti-CCR8 mechanism and early immune remodeling signals, Coherus Oncology Inc. (CHRS) is aligning scientific visibility with commercial expansion. LOQTORZI continues to gain traction in nasopharyngeal carcinoma, and with trial readouts expected in 1H 2026 and Q3 earnings due November 6, the company is entering a catalyst-heavy stretch that could reshape its immuno-oncology footprint.
CHS-114 Spotlight
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.